| First Author | Fontes-Oliveira CC | Year | 2018 |
| Journal | Sci Rep | Volume | 8 |
| Issue | 1 | Pages | 16302 |
| PubMed ID | 30389963 | Mgi Jnum | J:268747 |
| Mgi Id | MGI:6271966 | Doi | 10.1038/s41598-018-34362-2 |
| Citation | Fontes-Oliveira CC, et al. (2018) Effects of metformin on congenital muscular dystrophy type 1A disease progression in mice: a gender impact study. Sci Rep 8(1):16302 |
| abstractText | Congenital muscular dystrophy with laminin alpha2 chain-deficiency (LAMA2-CMD) is a severe muscle disorder with complex underlying pathogenesis. We have previously employed profiling techniques to elucidate molecular patterns and demonstrated significant metabolic impairment in skeletal muscle from LAMA2-CMD patients and mouse models. Thus, we hypothesize that skeletal muscle metabolism may be a promising pharmacological target to improve muscle function in LAMA2-CMD. Here, we have investigated whether the multifunctional medication metformin could be used to reduce disease in the dy(2J)/dy(2J) mouse model of LAMA2-CMD. First, we show gender disparity for several pathological hallmarks of LAMA2-CMD. Second, we demonstrate that metformin treatment significantly increases weight gain and energy efficiency, enhances muscle function and improves skeletal muscle histology in female dy(2J)/dy(2J) mice (and to a lesser extent in dy(2J)/dy(2J) males). Thus, our current data suggest that metformin may be a potential future supportive treatment that improves many of the pathological characteristics of LAMA2-CMD. |
